Despite currently available treatments for dyslipidemia, many patients do not reach therapeutic LDL-C goals and others sustain major CV events, even while being treated with adequate doses of medication. LDL-C lowering by inhibiting the action of proprotein convertase subtilisin kexin type 9 (PCSK9) appears to be a promising new dyslipidemia treatment.
Qualified Participants Must:
Be 18 years of age, or older
Have an LDL (“bad cholesterol”) value between 70-100
Have some form of cardiovascular risk or disease
Be taking Lipitor, Zocor or Crestor for high cholesterol
Qualified Participants May Receive:
Receive $50.00 per visit
Study medications provided.
No cost to participate
No insurance needed
No change in your doctor
Completely voluntary, no obligation to continue.